Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Study sponsor: Altimmune, Inc. · ALT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2018-03-07Actual
Enrollment · participants60Actual
Source updated2024-04-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.